Semaglutide's U.S. label now covers six approved uses across three brand families
Six approved uses now sit under one molecule, but each semaglutide product covers different conditions, which shapes what insurers will pay for.
Semaglutide is now approved by the FDA for six distinct uses in the United States, spread across the Ozempic, Wegovy and Rybelsus brands. The six are type 2 diabetes, cardiovascular risk reduction in people with type 2 diabetes, chronic kidney disease in people with type 2 diabetes, chronic weight management, cardiovascular risk reduction in people with obesity or overweight, and noncirrhotic MASH with moderate to advanced liver fibrosis [1][2].
The uses are not interchangeable between products. Ozempic injection, first approved on December 5, 2017, is indicated to improve blood sugar in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [2]. Ozempic tablets cover type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes who are at high risk for those events. That tablet was formerly the Rybelsus R2 formulation and was rebranded as Ozempic tablets on January 30, 2026 [2]. Rybelsus, first approved September 20, 2019, covers type 2 diabetes and cardiovascular risk reduction in type 2 diabetes [2].
Wegovy carries the other three uses. The injection, first approved June 4, 2021, is indicated to reduce excess weight and maintain weight loss in adults with obesity, in adults with overweight who have at least one weight-related condition, and in children aged 12 and older with obesity. It was approved on March 8, 2024 to reduce cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight, and it received accelerated approval on August 15, 2025 for noncirrhotic MASH with moderate to advanced fibrosis, consistent with stages F2 to F3 [1]. Wegovy tablets, approved December 22, 2025, cover weight reduction and cardiovascular risk reduction in the same obesity or overweight groups; the tablet form does not carry the MASH indication [1][2].
Ozempic's approval history describes it as the only GLP-1 receptor agonist approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [2]. Whether any other GLP-1 medicine matches semaglutide's full six-use range has not been reported.
Novo Nordisk has also expanded the Wegovy injection line. The FDA approved Wegovy HD, a 7.2 mg dose, on March 19, 2026 [1].
Why it matters for patients
Which semaglutide product a person is offered depends on what that product is approved to treat. Someone with type 2 diabetes and heart disease falls under the Ozempic and Rybelsus labels. Someone seeking weight management or treatment for liver scarring falls under the Wegovy label. Because insurers often tie coverage to the approved indication, the same molecule can be covered for one patient and denied for another.
The labels state that Wegovy should not be used with another semaglutide-containing product or with any other GLP-1 receptor agonist [1]. Both the Wegovy and Ozempic labels carry a boxed warning about thyroid C-cell tumors, plus warnings about acute pancreatitis, gallbladder disease, low blood sugar, acute kidney injury, increased heart rate, and diabetic retinopathy complications in people with type 2 diabetes [1][2]. Side effects reported in at least 5 percent of patients include nausea, vomiting, diarrhea, abdominal pain and constipation [1][2].
Wegovy's MASH approval is accelerated, based on improvement in MASH and fibrosis rather than on demonstrated long-term clinical benefit. Continued approval for that use may depend on a confirmatory trial [1].
What happens next
No date for that confirmatory MASH trial has been disclosed in the approval histories [1]. Novo Nordisk introduced the Ozempic pill with U.S. availability stated for the second quarter of 2026 [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.